South by South Lawn: A White House Festival of Ideas, Art, and Action

SXSL is a presidential initiative to bring together creative minds to make a positive difference in our country. Leaders in various fields will gather from across the nation to showcase how they are solving some of the toughest challenges in their own unique and innovative ways. On Monday, October 3, our lab will demonstrate our own efforts at answering the presidential call to action to accelerate cancer research and end cancer as we know it.

Visitors to the Cancer Moonshot booth will experience what it’s like to be a cancer patient from a clinical trial perspective with USC’s Analytical Tools to Objectively Measure Human Performance (ATOM-HP). We will demonstrate how we are using technology to continually monitor the well-being of patients to achieve the best measure of health when combined with physician assessed performance status. Visitors will get a glimpse into the future of patient care and experience how an Internet of Things (IoT) approach is enabling greater collaboration between cancer patients, physicians, and scientists. READ MORE>>>

Convergence Science Initiative – Cancer: CSI-Cancer

  • CSI Cancer is focused on improving the lives of cancer patients through scientific insights relevant to individual patients.CSI_Flower
  • CSI Cancer at USC is led by Dr. Peter Kuhn (email: kuhn42@usc.edu) and each project is led by a team comprised of patients, medical doctors, scientists and students focused on solving the clinical challenge through basic science breakthroughs that can be translated into real world solutions.

cancerbasesideblue (1)Basic yet critical information about most cancers and how they spread through the body just isn’t readily available. Today, CancerBase, a grassroots collaboration of patients, scientists, and social media volunteers, will go live with a way to connect patients all around the world to solve this problem, providing critical information to patients. Our goal is to bring together millions of patients to anonymously contribute the “what, when, and where” of their cancers, empowering themselves, each other, and scientists to see cancer more clearly. READ MORE>>>

CSI Cancer and the Kuhn laboratory at USC are proud to be part of CancerBase.

Recent News

The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupWednesday, November 29th, 2017 at 10:02am
The work entitled “Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay” by M. Rodriguez-Lee and colleagues is now posted as an Early Online Release at the website of Archives of Pathology & Laboratory Medicine. Congratulations to the authors!

The goal of the study was the evaluation of 2 preanalytic variables on the enumeration and downstream characterization of CTCs as an essential step toward clinical
implementation of fluid biopsies that seek to identify and characterize rare cells. A total of 100 breast cancer patients were enrolled in the OPTICOLL (OPTImization of blood COLLection) study at Billings Clinic (Billings, Montana) and Duke University (Durham, North Carolina). Blood samples were evaluated using the HD-SCA workflow. Performance of the assay in terms of rare cell enumeration and single-cell genomics was compared.

The results of this study provide an important framework for understanding how preanalytic variables can impact the fluid biopsy test results. The HD-SCA performance differences that were quantified may be used as a best practices guide for site-specific implementation into patient care and/or research biorepository processes. In addition, Standard Operating Procedures (SOPs) that were established under the OPTICOLL program with a scientific advisory team including representatives from the National Cancer Institute, the College of American Pathologists, and academic institutions, are now being implemented as part of the Blood Profiling Atlas in Cancer.

Read the full text at: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2016-0483-OA
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupWednesday, November 29th, 2017 at 9:00am
At Convergence Science Initiative (CSI) – Cancer, founded by Prof. Peter Kuhn, each project is led by a team of patients, medical doctors, scientists and students focused on improving the lives of cancer patients through scientific insights relevant to individual patients. The multidisciplinary initiative quantifies how cancer evolves over time, forecasts how an individual’s cancer will progress and quantifies health.

CSI-Cancer researchers 1) have developed mathematical models to forecast cancer survival rates, 2) used wearable technology and smartphones to improve cancer treatment (Analytical Technologies to Objectively Measure Human Performance, ATOM-HP), and 3) created an international cancer mapping initiative that enables patients to use social media to securely and anonymously share their cancer data (CancerBase).

The grant from Phase ONE Foundation will expand the innovative immersive cancer module of The University of Southern California's Iovine and Young Academy to a full-scale four-year undergraduate track that applies the Academy's proven interdisciplinary educational model to the field of health to drive innovation in patient care. The undergraduate track is looking to launch as early as Fall 2019.
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupThursday, November 23rd, 2017 at 2:20pm
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupThursday, November 16th, 2017 at 11:20am
Learn more about Dr. Nieva, a key member of the Kuhn-Hicks family.
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research Group shared University of Southern California's post.Wednesday, November 15th, 2017 at 6:34am
The Cancer Fluid Biopsy Research Group
University of Southern California
It's been just about two weeks since the USC Michelson Center for Convergent Bioscience officially opened - but as researcher Peter Kuhn describes, moving in will be a delicate process conducted over the next several months!
The Cancer Fluid Biopsy Research Group
The Cancer Fluid Biopsy Research GroupFriday, November 3rd, 2017 at 8:52am
A look inside our new home!
The new center comes with the responsibility to make significant scientific breakthroughs that improve human well-being.